State pharmacy boards could lose their authority to regulate pharmacist compounding activities under a controversial new legislative plan being hammered out on Capitol Hill. The proposal, still in draft form at press time, was being circulated by a bipartisan group of senators headed by Senate Committee on Health, Education, Labor, and Pensions Chairman Edward Kennedy (D, Mass).
Under the plan, responsibility for regulating drug compounding would shift to the FDAan agency that has shown little appreciation for the traditional right of pharmacists to compound medicines. The National Community Pharmacists Association and several other national and state pharmacy groups are urging federal lawmakers to reject this legislative proposal and support pharmacy's long-standing authority to compound drugs.
Visit ePharmacy Times at www.pharmacytimes.com/articleNewsletter.cfm?ID=4503 for a related article about the pharmacy organizations'concerns.
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs